home / stock / mdwd / mdwd news

MDWD News and Press, MediWound Ltd. From 12/05/22

Stock Information
Company Name: MediWound Ltd.
Stock Symbol: MDWD
Market: NASDAQ
Website: mediwound.com
Menu
MDWD MDWD Quote MDWD Short MDWD News MDWD Articles MDWD Message Board
Get MDWD Alerts

News, Short Squeeze, Breakout and More Instantly...
MDWD - MediWound Announces a 1-for-7 Reverse Share Split

YAVNE, Israel, Dec. 05, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (“ MediWound ” or the “ Company ”), a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announc...
MDWD - MediWound Ltd. (MDWD) Q3 2022 Earnings Call Transcript

MediWound Ltd. (MDWD) Q3 2022 Earnings Conference Call November 15, 2022, 8:30 am ET Company Participants Monique Kosse - MD, LifeSci Advisors Ofer Gonen - CEO Boaz Gur-Lavie - CFO Conference Call Participants Josh Jennings - Cowen Francois Briseb...

MDWD - MediWound GAAP EPS of -$0.13 misses by $0.03, revenue of $5.8M beats by $1.2M

MediWound press release ( NASDAQ: MDWD ): Q3 GAAP EPS of -$0.13 misses by $0.03 . Revenue of $5.8M (-8.9% Y/Y) beats by $1.2M . For further details see: MediWound GAAP EPS of -$0.13 misses by $0.03, revenue of $5.8M beats by $1.2M

MDWD - MediWound Reports Third Quarter 2022 Financial Results and Provides Company Update

$30.5 million in gross proceeds raised; operating cash runway through 2025 NexoBrid PDUFA date of January 1, 2023; Upon approval, NexoBrid expected to generate meaningful revenues Company f ocus ed on the billion-dollar market ...
MDWD - MediWound Q3 2022 Earnings Preview

MediWound ( NASDAQ: MDWD ) is scheduled to announce Q3 earnings results on Tuesday, November 15th, before market open. The consensus EPS Estimate is -$0.10 (+16.7% Y/Y) and the consensus Revenue Estimate is $4.6M (-27.8% Y/Y). Over the last 1 year, MDWD has beaten EP...

MDWD - MediWound's EscharEx Featured in Paper as a Potential Paradigm Shift Towards Non-Surgical Wound Bed Preparation in DFUs

Paper published in the November 2022 issue of Podiatry Management (Robert J. Snyder, DPM, Cyaandi Dove, DPM, and Vickie Driver, DPM, MS) YAVNE, Israel, Nov. 09, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ: MDWD), a fully integrated biopharmaceutical company focused on next...

MDWD - MediWound to Report Third Quarter 2022 Financial Results

YAVNE, Israel, Nov. 03, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced that the Company will release its financial results for the th...
MDWD - MediWound Announces Formation of Strategic Advisory Board

YAVNE, Israel, Oct. 25, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ: MDWD), a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced the establishment of a Strategic Advisory Board (SAB). The ina...

MDWD - MediWound's EscharEx® Featured in Oral and Poster Presentations at the Symposium on Advanced Wound Care (SAWC) Fall 2022

YAVNE, Israel, Oct. 18, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced that positive clinical data from the Company’s EscharEx...

MDWD - MediWound Announces Closing of the Concurrent Registered Direct and Private Placement Offerings

YAVNE, Israel, Oct. 07, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ: MDWD), a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced the closing of its previously announced registered direct and ...
Previous 10 Next 10